THE IMPORTANCE OF SCHEDULE AND DRUG DOSE INTENSITY IN COMBINATIONS OF MODALITIES

被引:16
作者
KALLMAN, RF
机构
[1] Department of Radiation Oncology, Stanford University School of Medicine, Stanford
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1994年 / 28卷 / 03期
关键词
COMBINED MODALITIES; SCHEDULE DEPENDENCE; DOSE INTENSITY; CISPLATIN PLUS IRRADIATION; THERAPEUTIC GAIN; INTERLEUKIN; 1;
D O I
10.1016/0360-3016(94)90205-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To review a series of laboratory experiments that have been conducted to investigate the degree to which therapeutic effectiveness is a function of the scheduling of two or more therapeutic agents. Methods and Materials: The therapeutic effectiveness of a few combinations of modalities (fractionated irradiation + cis-DDP alone and with 5FU, cyclophosphamide, or etoposide) has been evaluated systematically for a large number of schedules. For every such schedule, therapeutic gain factors were calculated as the ratio of effectiveness for tumor growth inhibition to each of three normal tissue endpoints in laboratory mice: duodenal crypt cell survival, pneumonitis (breathing rate at 5 months after treatment), and pulmonary fibrosis (breathing rate at 10 months). Results: For every combination tested, at least one schedule was distinctly therapeutically superior to the others. Most often, the greatest therapeutic gain was achieved with divided doses of cis-DDP administered simultaneously with five daily x-ray dose fractions. Even greater gain was found when cyclophosphamide was administered as a single bolus 1 day before fractionated cis-DDP/irradiation. Still greater therapeutic gain was achieved by protecting against normal tissue toxicity by administering the cytokine, interleukin 1, prior to chemotherapy-radiotherapy. Conclusion: Performing experiments of the type described in this paper can be of great value in the optimization of treatment with combinations of agents or modalities.
引用
收藏
页码:761 / 771
页数:11
相关论文
共 27 条
[1]   THERAPEUTIC ENHANCEMENT IN MICE BY CLINICALLY RELEVANT DOSE AND FRACTIONATION SCHEDULES OF CIS-DIAMMINEDICHLOROPLATINUM(II) AND IRRADIATION [J].
BARTELINK, H ;
KALLMAN, RF ;
RAPACCHIETTA, D ;
HART, GAM .
RADIOTHERAPY AND ONCOLOGY, 1986, 6 (01) :61-74
[2]  
DORIE MJ, 1989, P SOC EXP BIOL MED, V191, P23
[3]   PROTECTION BY INTERLEUKIN-1 AGAINST LUNG TOXICITY CAUSED BY CYCLOPHOSPHAMIDE AND IRRADIATION [J].
DORIE, MJ ;
BEDARIDA, G ;
KALLMAN, RF .
RADIATION RESEARCH, 1991, 128 (03) :316-319
[4]   INTERLEUKIN-1 MODIFICATION OF THE EFFECTS OF CYCLOPHOSPHAMIDE AND FRACTIONATED-IRRADIATION [J].
DORIE, MJ ;
KALLMAN, RF ;
CEBULSKAWASILEWSKA, A .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (02) :311-314
[5]   MODIFICATION OF THE EFFECTS OF CONTINUOUS LOW-DOSE RATE IRRADIATION BY CONCURRENT CHEMOTHERAPY INFUSION [J].
FU, KK ;
RAYNER, PA ;
LAM, KN .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1984, 10 (08) :1473-1478
[6]  
HANCOCK SL, 1991, CANCER RES, V51, P2280
[7]  
HRYNIUK WM, 1990, EFFECTS THERAPY BIOL, P93
[8]   SCHEDULE-DEPENDENT THERAPEUTIC GAIN FROM THE COMBINATION OF FRACTIONATED-IRRADIATION PLUS C-DDP AND 5-FU OR PLUS C-DDP AND CYCLOPHOSPHAMIDE IN C3H/KM MOUSE MODEL SYSTEMS [J].
KALLMAN, RF ;
RAPACCHIETTA, D ;
ZAGHLOUL, MS .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 20 (02) :227-232
[9]  
KALLMAN RF, 1992, FRONT RADIAT THER ON, V26, P31
[10]  
KANAZAWA H, 1988, CANCER RES, V48, P3158